Oppenheimer & Co’s 9 Meters Biopharma NMTR Stock Holding History

Oppenheimer & Co’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-545	Closed	-$14K	–	1599
2021 Q3	$14K	Hold	545	–	–	﹤0.01%	1483
2021 Q2	$12K	Buy	+545	New	+$13.4K	﹤0.01%	1500

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Oppenheimer & Co's NMTR Position: Q4 2021 in Review

Oppenheimer & Co sold out of 9 Meters Biopharma (NMTR) in Q4 2021, closing a stake of 545 shares — an estimated $14K sold.

Oppenheimer & Co first reported a position in NMTR in Q2 2021 and held it in 2 quarters. The position peaked at $14K in Q3 2021. 104 funds tracked by Wall St. Rank hold NMTR as of Q4 2021.

Oppenheimer & Co reported no remaining 9 Meters Biopharma position as of Q4 2021 after selling out during the quarter.
Oppenheimer & Co sold 545 9 Meters Biopharma shares in Q4 2021, an estimated $14K.
Oppenheimer & Co first reported a position in 9 Meters Biopharma in Q2 2021 and held it in 2 quarters.
Oppenheimer & Co's 9 Meters Biopharma position peaked at $14K in Q3 2021.
104 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2021.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.